Noveome Biotherapeutics, Inc. is featured on the ninth Annual Digital Neurodegenerative Drug Growth Summit

PITTSBURGH – (BUSINESS WIRE) – Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next generation biologics to promote and restore the cellular integrity of inflamed or damaged tissues, today announced that Larry Brown, Sc.D. , Executive Vice President and Chief Scientific Officer at Noveome will be giving a live presentation during the 9th Annual Virtual Neurodegenerative Drug Development Summit, entitled “Exploring Cellular Approaches to Neurodegenerative Drug Discovery”. The live presentation will be on Wednesday, February 24, 2021 at 5:00 p.m. EST.

Dr. Brown will present the evolution of Noveome’s neuroprotection research and development program from “Cell Therapy to Secretome”. His talk will include neurorepair data for acute CNS injuries and chronic neuritis. The studies examined various routes of administration ranging from the direct intracranial, intravenous, and intraperitoneal delivery of AMP cells to the non-invasive, targeted intranasal delivery of Noveome’s proprietary ST266 secretome. The route for the translation to the clinic is also discussed.

About Noveome Biotherapeutics, Inc.

Pittsburgh-based Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics to promote and restore the cellular integrity of inflamed or damaged tissues. Noveome has completed an open phase 2 clinical trial demonstrating the utility of ST266 in the healing of persistent corneal epithelial defects (PEDs) and is currently planning follow-up clinical trials to further characterize the efficacy and safety of ST266 for the treatment of PEDs . In addition to the Phase 2 study described above, ST266 is also being evaluated in an open-label Phase 1 clinical trial to determine the safety of ST266 for intranasal transcribriform delivery from the nose to the brain and eye. Noveome has started a program to test ST266 to treat the severe inflammatory response associated with COVID-19 infections and post-COVID-19 symptoms in many COVID-19 patients. More information is available at www.noveome.com.

Comments are closed.